Bleeding Disorders Treatment Market Size, Business Profiles and Forecast to 2023
Market
Overview:
According to
Market Research Future (MRFR), the global Bleeding
Disorders Treatment Market Size is expected to garner a CAGR of over 10.0% over
the assessment period (2018-2023). The demographic drivers of the market
include the growing incidence of bleeding disorders and the growing population.
According to the National Hemophilia Foundation hemophilia affects about 20,000
people in the United States and more than 400,000 people globally. Platelet
disorders have an incidence of 1900to 6400 per 10000a year.
Bleeding Disorders Treatment
Market – Competitive Landscape
The bleeding disorders
treatment market is fragmented and highly competitive due to the presence of
plethora of small and large players. A large market is captive owing to
purchase by public health sector. Manufacturers rely on close collaboration and
partnerships with public players and programmes so as to tap the government
purchase of drugs used for bleeding disorders.
The free market is
dominated by large companies having a premium product using advanced
technologies such as recombinant DNA, advanced clotting factors and others.
Companies are also investing in R&D activities so as to develop new drug
molecules. Developments in associated sciences such as protein analysis,
recombinant technology is resulting in increased collaboration between players.
Major
Players:
·
Pfizer Inc
·
Bayer Pharmaceuticals
·
Biogen Inc
·
BDI Pharma
·
CSL Behring
·
Grifols
·
Sun Pharmaceutical
Industries Ltd.
·
Octapharma
·
Ferring Pharmaceuticals
·
Novo Nordisk A/S
Global Bleeding Disorders Treatment
Market – Segments
By Type : Hemophilia A, Hemophilia B,
Von Willebrand Disease (vWD), among others.
By Drug Class : Plasma-derived Coagulation
Factor Concentrates, Recombinant Coagulation Factor Concentrate, among others.
By Treatment : Medication, Desmopressin
(DDAVP), Hormone replacement therapy, Contraceptives,
Anti-fibrinolytic/clot-stabilizing drugs, Fibrin sealants, Drugs applied to cuts,
among others.
By End-users : Hospitals, Clinics, Research
Institutes, among others.
By Regions :
North America, Europe, Asia Pacific, and the Rest-of-the-World.
Global Bleeding Disorders Treatment
Market – Regional Analysis
The Americas is projected
to lead the bleeding disorders treatment market in the forecast period.
Increasing healthcare awareness, advancement in technology, medical tourism are
some other factors that boost the growth of the market. According to the Centers
for Disease Control and Prevention, Hemophilia A affects 1 in 5,000 male births
and about 400 babies are born with hemophilia Each year.
The European market is
expected to hold the second largest market share. The market is expected to
witness growth owing to the rising patient population, changing lifestyle, and
growing elderly population. This is expected to provide favorable backgrounds
for the market to grow. According to annual report survey of 2015 by World
Federation of Hemophilia, it is estimated that there were 523 million people
suffering from hemophilia, 309 suffering from von Willebrand disease and 145
million people from bleeding disorders in Denmark.
Asia-Pacific is projected
to be the fastest growing region for the global bleeding disorders treatment in
2018. According to the annual report survey of 2015 by the World Federation of
Hemophilia, it is estimated that there were 7,451 million people suffering from
hemophilia and 1,950 suffering from von Willebrand disease in Russia. According
to annual report survey of 2015 by World Federation of Hemophilia, it is
estimated that there were 131 million people suffering from hemophilia, 2
suffering from von Willebrand disease and 7 million people from bleeding
disorders in Hong Kong.
The Middle East and Africa
accounts for the least share due to stringent government policies and low per
capita income. According to annual report survey of 2015 by World Federation of
Hemophilia, it is estimated that there were 2,206 million people suffering from
hemophilia, 632 million people suffering from von Willebrand disease and 223
million people from bleeding disorders in South Africa
Comments
Post a Comment